Csl investor briefing
WebDec 10, 2015 · Investor R&D Briefing December 10, 2015 . 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of ... WebAug 18, 2024 · CSL Limited (OTCPK:CSLLY) Q4 2024 Earnings Conference Call August 17, 2024 8:00 PM ETCompany ParticipantsMark Dehring - Vice President, Investor RelationsPaul Perreault - Chief Executive...
Csl investor briefing
Did you know?
WebVifor Pharma is committed to improving the lives of patients around the world with the development of innovative pharmaceutical products. Our passion, values and ethics will continue to drive our approach to research and development activity as we continue to work closely with experts in all areas of medicine to develop new medicines and optimizing our … WebR&D Investor Briefing December 05, 2024. 2 Driven by Our Promise ... (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that ...
WebCFO Presentation to Retail Shareholder Meetings, Canberra & Brisbane. PDF. Audio. 30 April. President (Seqirus) Presentation to the Macquarie Australia Conference, Sydney. … WebOct 18, 2024 · CSL Ltd R&D Investor Briefing 2024 - Final. Fair Disclosure Wire; Linthicum [Linthicum]. 18 Oct 2024. ... MARK DEHRING, HEAD OF IR, CSL LIMITED: Ladies and gentlemen, welcome to CSL's Annual Research and Development Briefing. Online with us today is Dr. Bill Mezzanotte, Executive Vice President, Head of Research and …
WebPrior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas. In 2024, Bill was named to the Board of Directors of the Philadelphia ... WebAug 16, 2024 · CSL Limited (ASX:CSL; USOTC:CSLLY) will announce its 2024 full year result on Wednesday 17 August 2024. A briefing for investors and analysts will be held at 11.00am Australian Eastern Standard Time on the same day. This briefing will be webcast on the Company website at www.csl.com in the 'Investors' section. An archived copy of …
WebOct 17, 2024 · CSL [] released an investor briefing presentation on Monday, providing further detail on its Vifor acquisition, along with a business and strategy update.CSL …
WebNov 3, 2024 · CSL Behring 03 Nov 2024. MELBOURNE, Australia and KING OF PRUSSIA, Pennsylvania – 03/02 November 22 -- Next-Generation mRNA, Gene Therapy, Plasma … daily lotto common pairsWebFY2024 presentations and briefings. President Petroleum investor meeting with Barrenjoey - Speaker notes pdf 247 KB President Petroleum investor meeting with Barrenjoey - Presentation pdf 1.66 MB ESG Roundtable (21 Sept 2024) pdf 2.02 MB ESG Roundtable speaking notes (21 Sept 2024) pdf 1.18 MB BHP Jefferies Virtual Base … daily logs templateWebDec 10, 2015 · Investor R&D Briefing December 10, 2015 . 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these … daily mail doctors surgeryWebInnovation is in our DNA. Investment in R&D is an important driver for CSL’s future growth. New and exciting opportunities allow us to address previously unmet patient needs and … daily look clothing reviewsWebNov 3, 2024 · Authorised by Fiona Mead , Company Secretary For further information, please contact: Investors: Bernard Ronchi Stephen McKeon Investor Relations … daily icu costWeb– CSL will hold its annual Research and Development briefing today; the presentation is attachedfor the information of investors. Amongst other achievements, CSL is pleased to highlight the following: • Its work across a number of programs across our R&D platforms to prevent and treat COVID-19. • CSL’s AEGIS-II Phase 3 study of CSL112 ... daily log for construction projectsWebThe CSL Limited share price will be on watch on Tuesday when it holds its annual research and development (R&D) investor briefing. In FY 2024 the biotherapeutics giant invested US$922 million in ... daily lotto draw order results